SCHEMBL22323732

SCHEMBL22323732

COc1cc(NC=C2C(=O)OC(C)(C)OC2=O)ncc1Br

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 16/20 0.53
HSD17B10 Q99714 4/20 0.52
CASP1 P29466 2/20 0.52
CASP7 P55210 2/20 0.52
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
SIRT1 Q96EB6 1/20 0.40
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
RAB9A P51151 1/20 0.39
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17383454 0.82 ALDH1A1 (0.53) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL6354110 0.78 ALDH1A1 (0.62) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL30616291 0.78 ALDH1A1 (0.62) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL25284932 0.76 ALDH1A1 (0.56) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL30465757 0.76 ALDH1A1 (0.56) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL15010761 0.75 ALDH1A1 (0.62) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL21617904 0.75 ALDH1A1 (0.66) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL29100739 0.74 ALDH1A1 (0.57) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL29701577 0.74 ALDH1A1 (0.57) ALDH1A1HSD17B10CASP1CASP7MAPK1
SCHEMBL14358353 0.74 ALDH1A1 (0.60) ALDH1A1HSD17B10CASP1CASP7MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 ALDH1A1 4181/4885HSD17B10 2034/4885CASP1 3456/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 ALDH1A1 3032/4885HSD17B10 864/4885CASP1 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.